International Journal of Clinical Oncology最新文献

筛选
英文 中文
Evaluating the impact of atezolizumab on febrile neutropenia occurrence in patients with NSCLC undergoing chemotherapy in Japan: a real-world post-marketing database study.
IF 2.4 3区 医学
International Journal of Clinical Oncology Pub Date : 2024-12-16 DOI: 10.1007/s10147-024-02669-y
Sayuri Nakane, Akinori Yuri, Yuki Miyano, Kana Yamada, Erika Nakatsuji, Nobuki Takei, Yasuhiro Igarashi, Ryousuke Harada
{"title":"Evaluating the impact of atezolizumab on febrile neutropenia occurrence in patients with NSCLC undergoing chemotherapy in Japan: a real-world post-marketing database study.","authors":"Sayuri Nakane, Akinori Yuri, Yuki Miyano, Kana Yamada, Erika Nakatsuji, Nobuki Takei, Yasuhiro Igarashi, Ryousuke Harada","doi":"10.1007/s10147-024-02669-y","DOIUrl":"https://doi.org/10.1007/s10147-024-02669-y","url":null,"abstract":"<p><strong>Background: </strong>Febrile neutropenia (FN) is a recognised adverse event associated with chemotherapy. This study investigates the impact of atezolizumab, an immune checkpoint inhibitor, on the incidence of FN in patients with non-small cell lung cancer receiving concurrent chemotherapy in Japan.</p><p><strong>Methods: </strong>This post-marketing database study was conducted using data from patients with non-small cell lung cancer provided by Medical Data Vision Co., Ltd. covering April 2008 to present. The primary outcome measured was FN incidence, and its causal association with atezolizumab use was examined by comparing the atezolizumab plus bevacizumab plus carboplatin plus paclitaxel [ABCP])-containing regimen to the BCP control group. The data period was from 1 September, 2015, to 31 December, 2021, including approval date of this drug, 21 December, 2018.</p><p><strong>Results: </strong>The database identified 301 subjects for the ABCP regimen (exposure) group, 44 for the BCP regimen (cohort design control) group during the same period, and 207 for BCP regimen (historical cohort design control) group before the approval of atezolizumab. For historical cohort design, the incidence and adjusted incidence ratios of febrile neutropenia in the exposure group to the control group were 6.13 (95% CI 2.78-13.49) and 8.19 (95% CI 3.79-25.33), respectively. Sensitivity analysis showed FN occurred in 17% (52/301) of the exposure group, 4.5% (2/44) of the cohort design control group, and 3% (7/207) of the historical cohort design control group.</p><p><strong>Conclusions: </strong>The incidence of FN was higher in the exposure group. Considering the study results, special caution is needed for FN occurrence in patients receiving atezolizumab.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of presurgical systemic therapy on perioperative outcomes of renal cell carcinoma with inferior vena cava tumor thrombus.
IF 2.4 3区 医学
International Journal of Clinical Oncology Pub Date : 2024-12-12 DOI: 10.1007/s10147-024-02680-3
Kotaro Suzuki, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Akihisa Yao, Jun Teishima, Hideaki Miyake
{"title":"Impact of presurgical systemic therapy on perioperative outcomes of renal cell carcinoma with inferior vena cava tumor thrombus.","authors":"Kotaro Suzuki, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Akihisa Yao, Jun Teishima, Hideaki Miyake","doi":"10.1007/s10147-024-02680-3","DOIUrl":"https://doi.org/10.1007/s10147-024-02680-3","url":null,"abstract":"<p><strong>Background: </strong>Surgery for inferior vena cava tumor thrombus (IVC-TT) in patients with renal cell carcinoma (RCC) is highly invasive and is associated with perioperative mortality. This study aimed to assess the efficacy of presurgical systemic therapy (PT) on perioperative outcomes in RCC patients with IVC-TT.</p><p><strong>Methods: </strong>A total of 68 patients with right-sided RCC and level ≥ II IVC-TT were included in this study. The tumor response to PT was investigated, and we compared surgical outcomes and perioperative complications between patients with PT (n = 23) and those who underwent immediate surgical resection (non-PT, n = 45).</p><p><strong>Results: </strong>In the PT group, while 15 patients were treated with tyrosine kinase inhibitors (TKIs) alone, a combination of immune-oncology (IO) therapy and TKIs (IO + TKI) was used in 8 patients. Eleven of 23 (47.8%) patients in the PT group showed a reduction in the level of TT. PT significantly reduced the operation time, intraoperative blood loss, the need for extracorporeal circulation, the incidence of grade ≥ III perioperative complications, and the duration of hospitalization after surgery.</p><p><strong>Conclusion: </strong>Our findings suggest that PT may be effective in reducing surgical invasiveness in RCC patients with IVC-TT. Further prospective studies are needed to identify the optimal drug regimen for PT and to clarify its survival benefits.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.
IF 2.4 3区 医学
International Journal of Clinical Oncology Pub Date : 2024-12-10 DOI: 10.1007/s10147-024-02676-z
Yasutaka Yamada, Kodai Sato, Shinichi Sakamoto, Takuya Tsujino, Sinpei Saito, Kazuki Nishimura, Tatsuo Fukushima, Ko Nakamura, Yuki Yoshikawa, Tomohisa Matsunaga, Ryoichi Maenosono, Manato Kanesaka, Takayuki Arai, Tomokazu Sazuka, Yusuke Imamura, Kazumasa Komura, Kazuo Mikami, Kazuyoshi Nakamura, Satoshi Fukasawa, Kazuto Chiba, Yukio Naya, Maki Nagata, Atsushi Komaru, Hiroomi Nakatsu, Haruhito Azuma, Tomohiko Ichikawa
{"title":"Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.","authors":"Yasutaka Yamada, Kodai Sato, Shinichi Sakamoto, Takuya Tsujino, Sinpei Saito, Kazuki Nishimura, Tatsuo Fukushima, Ko Nakamura, Yuki Yoshikawa, Tomohisa Matsunaga, Ryoichi Maenosono, Manato Kanesaka, Takayuki Arai, Tomokazu Sazuka, Yusuke Imamura, Kazumasa Komura, Kazuo Mikami, Kazuyoshi Nakamura, Satoshi Fukasawa, Kazuto Chiba, Yukio Naya, Maki Nagata, Atsushi Komaru, Hiroomi Nakatsu, Haruhito Azuma, Tomohiko Ichikawa","doi":"10.1007/s10147-024-02676-z","DOIUrl":"https://doi.org/10.1007/s10147-024-02676-z","url":null,"abstract":"<p><strong>Background: </strong>This study investigated the characteristics of prostate-specific antigen (PSA) dynamics when androgen receptor signaling inhibitor (ARSI), or vintage agent (bicalutamide) was used for patients with metastatic hormone-sensitive prostate cancer (mHSPC).</p><p><strong>Patients and methods: </strong>A total of 213 mHSPC patients from each of the ARSI and bicalutamide groups treated between 2015 and 2022 were selected from multiple institutions using propensity score-matched analysis to align backgrounds. PSA progression-free survival (PFS) and overall survival (OS) were assessed. PSA level at 3 months, PSA nadir level, and time to PSA nadir were examined to analyze of PSA kinetics.</p><p><strong>Results: </strong>ARSI treatment significantly improved PSA PFS compared to bicalutamide (P = 0.0063), although no significant difference in OS was seen (P = 0.3134). No significant differences were observed between treatment groups in median PSA levels at 3 months (1.47 vs 0.52 ng/ml, P = 0.3042) or PSA nadir levels (0.263 vs 0.1345 ng/ml, P = 0.1228). Bicalutamide treatment demonstrated longer time to nadir than ARSI in progression-free cases (median: 243 vs 213.5 days, P = 0.0003). Survival tree analysis found that PSA nadir ≤ 1.5 ng/ml and time to nadir ≥ 145 days were the optimal cut-offs for best stratifying OS with bicalutamide, while PSA nadir ≤ 0.45 ng/ml and time to nadir ≥ 70 days were optimal with ARSI.</p><p><strong>Conclusion: </strong>No significant differences in PSA response was seen between groups; however, distinct optimal cut-offs were demonstrated for PSA nadir and time to nadir. The present findings will be useful for optimal PSA monitoring for mHSPC patients and for early identification of poor-prognosis populations.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1. 莫司珠单抗单药治疗日本复发性/难治性滤泡性淋巴瘤患者的有效性和安全性:FLMOON-1。
IF 2.4 3区 医学
International Journal of Clinical Oncology Pub Date : 2024-12-09 DOI: 10.1007/s10147-024-02662-5
Hideki Goto, Takahiro Kumode, Yuko Mishima, Keisuke Kataoka, Yoshiaki Ogawa, Nobuhiro Kanemura, Kazuyuki Shimada, Toshiki Uchida, Yukano Kuroe, Atsuko Kawasaki, Jotaro Sato, Takanori Teshima
{"title":"Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1.","authors":"Hideki Goto, Takahiro Kumode, Yuko Mishima, Keisuke Kataoka, Yoshiaki Ogawa, Nobuhiro Kanemura, Kazuyuki Shimada, Toshiki Uchida, Yukano Kuroe, Atsuko Kawasaki, Jotaro Sato, Takanori Teshima","doi":"10.1007/s10147-024-02662-5","DOIUrl":"https://doi.org/10.1007/s10147-024-02662-5","url":null,"abstract":"<p><strong>Background: </strong>In a global phase I/II study (GO29781; NCT02500407), single-agent mosunetuzumab had a manageable safety profile and induced durable complete responses in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma, including in patients with R/R follicular lymphoma (FL). In this analysis, the efficacy and safety of mosunetuzumab monotherapy were evaluated in an expansion cohort, FLMOON-1, in Japanese patients with R/R FL who had received  ≥ 2 prior lines of therapy in a phase I study (JO40295, jRCT2080223801).</p><p><strong>Methods: </strong>Mosunetuzumab was administered intravenously at the recommended phase II dose (with cycle 1 step-up dosing) for eight cycles or up to 17 cycles, or until disease progression or unacceptable toxicity. The pre-specified primary endpoint was Independent Review Facility (IRF)-assessed complete response rate (CRR; as best overall response). Secondary objectives included investigator (INV)-assessed CRR, INV- and IRF-assessed objective response rate (ORR), and safety.</p><p><strong>Results: </strong>At the data cutoff (October 13, 2023), 19 patients (median age 72 years) were evaluated. The IRF-assessed CRR and ORR were 68.4% and 78.9%, respectively; the INV-assessed CRR and ORR were 63.2% and 84.2%, respectively. Grade 3-4 adverse events (AEs) were observed in 89.5% of patients, with a low incidence of AEs leading to mosunetuzumab discontinuation (10.5%) and one fatal AE unrelated to mosunetuzumab. Cytokine release syndrome occurred in 47.4% of patients and were mostly Grade 1 in severity.</p><p><strong>Conclusion: </strong>These findings indicate mosunetuzumab has a consistent efficacy and manageable safety profile in Japanese patients with R/R FL compared with previously reported data from the global phase I/II study.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experience.
IF 2.4 3区 医学
International Journal of Clinical Oncology Pub Date : 2024-12-06 DOI: 10.1007/s10147-024-02667-0
Mayu Yunokawa, Akiko Abe, Xiaofei Wang, Yusuke Toyohara, Ryo Nimura, Takayuki Komoto, Satoki Misaka, Teruyuki Yoshimitsu, Ai Ikki, Mayumi Kamata, Shogo Nishino, Motoko Kanno, Atsushi Fusegi, Sachiho Netsu, Yoichi Aoki, Makiko Omi, Terumi Tanigawa, Sanshiro Okamoto, Hidetaka Nomura, Hiroyuki Kanao
{"title":"The efficacy and safety of lenvatinib plus pembrolizumab in vulnerable patients with metastatic or recurrent endometrial cancer: a single institution experience.","authors":"Mayu Yunokawa, Akiko Abe, Xiaofei Wang, Yusuke Toyohara, Ryo Nimura, Takayuki Komoto, Satoki Misaka, Teruyuki Yoshimitsu, Ai Ikki, Mayumi Kamata, Shogo Nishino, Motoko Kanno, Atsushi Fusegi, Sachiho Netsu, Yoichi Aoki, Makiko Omi, Terumi Tanigawa, Sanshiro Okamoto, Hidetaka Nomura, Hiroyuki Kanao","doi":"10.1007/s10147-024-02667-0","DOIUrl":"https://doi.org/10.1007/s10147-024-02667-0","url":null,"abstract":"<p><strong>Background: </strong>Effective management with second-line therapy with the lenvatinib + pembrolizumab regimen for patients with advanced endometrial cancer is necessary.</p><p><strong>Methods: </strong>This retrospective study enrolled patients with endometrial cancer treated with the lenvatinib + pembrolizumab regimen. We evaluated progression-free survival (PFS), overall survival (OS), safety for patients non-eligible for the KEYNOTE775 trial, aged ≥65 years, or with ECOG performance status 1-2.</p><p><strong>Results: </strong>Forty-five patients were analyzed: 21 (47%) were aged ˃ 65 years, 16 (36%) had performance status 1-2, and 15 (33%) were non-eligible for KEYNOTE775 trial participation. Overall, the median PFS was 8.5 months (95% confidence interval [CI] 4.6-12.4), and the median OS was 15.6 months (95% CI 9.4-NA). Median PFS was significantly shorter in patients not eligible for KEYNOTE775 participation and with performance status 1-2. The median OS was significantly shorter in patients with performance status 1-2. Grade ˃3 adverse events (AEs) occurred in 78% of patients who received the lenvatinib + pembrolizumab regimen. AEs resulted in lenvatinib dose reductions in 35 patients (78%) and lenvatinib and pembrolizumab discontinuation in 3 (7%) and 5 (11%), respectively. The median time to the first lenvatinib dose reduction was 1.5 (0.92-2.3) months in all patients and was significantly shorter in patients aged >65 years.</p><p><strong>Conclusions: </strong>The current regimen has favorable efficacy and manageable safety with appropriate dose reduction of lenvatinib in the real world. However, the efficacy may be inferior in patients with performance status 1 or 2, heavily treated patients, and those with organ dysfunction. The current treatment status should reflect real-world data relative to the medical environment and management.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovery and validation of Hsa-microRNA-3665 promoter methylation as a potential biomarker for the prognosis of esophageal squaous cell carcinoma.
IF 2.4 3区 医学
International Journal of Clinical Oncology Pub Date : 2024-12-04 DOI: 10.1007/s10147-024-02656-3
Jinsong Zhou, Shuang Liu, Juwei Zhang, Qiaoyan Zeng, Zheng Lin, Rong Fu, Yulan Lin, Zhijian Hu
{"title":"Discovery and validation of Hsa-microRNA-3665 promoter methylation as a potential biomarker for the prognosis of esophageal squaous cell carcinoma.","authors":"Jinsong Zhou, Shuang Liu, Juwei Zhang, Qiaoyan Zeng, Zheng Lin, Rong Fu, Yulan Lin, Zhijian Hu","doi":"10.1007/s10147-024-02656-3","DOIUrl":"https://doi.org/10.1007/s10147-024-02656-3","url":null,"abstract":"<p><strong>Background: </strong>Methylation of microRNA (miRNA) promoters associated with diseases is a common epigenetic mechanism in the development of various human cancers. However, its relationship with prognosis in esophageal squamous cell carcinoma (ESCC) remains unclear. This study aims to explore the association between the methylation level of has-miR-3665 promoter and prognosis in ESCC.</p><p><strong>Methods: </strong>Human miRNA data were downloaded from miRbase, and we identified CpG islands of these human miRNAs by genomics browser analysis. MiRNA methylation levels were detected by methylation-specific high-resolution melting. Gene ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to explore the molecular mechanism of hsa-miR-3665. Cox regression analysis was used to investigate prognostic factors. The overall survival rate was predicted by a nomogram.</p><p><strong>Results: </strong>We found that 88 human miRNAs had promoter methylatio, of which 15 miRNAs were found to be epigenetically regulated in ESCC cells compared with their normal counterparts, including hsa-miR-3665. Meanwhile, hsa-miR-3665 expression was significantly lower in ESCC tumour tissue than in adjacent tissue (P = 0.03). GO and KEGG analyses demonstrated that the target genes are involved in protein transport, transcription regulator activity, MAPK and RAS signaling pathway. High hsa-miR-3665 promoter methylation levels were associated with a poor prognosis (HR = 3.89, 95% CI 1.11 ~ 13.55). Moreover, a nomogram incorporating the hsa-miR-3665 methylation level and clinical factors presented a good performance for predicting survival in the training and validation tests, with C-indices of 0.748 and 0.751, respectively.</p><p><strong>Conclusions: </strong>High hsa-miR-3665 promoter methylation levels may be a potential biomarker for the progression of ESCC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prospective changes in financial toxicity and health-related quality of life in patients with gynecologic cancer.
IF 2.4 3区 医学
International Journal of Clinical Oncology Pub Date : 2024-12-03 DOI: 10.1007/s10147-024-02668-z
Kazunori Honda, Yusuke Kajimoto, Shiro Suzuki, Masahiko Mori, Kohshiro Nakao, Anri Azuma, Takashi Shibutani, Shoji Nagao, Takahiro Koyanagi, Izumi Kohara, Shuko Tamaki, Midori Yabuki, Lida Teng, Ataru Igarashi
{"title":"Prospective changes in financial toxicity and health-related quality of life in patients with gynecologic cancer.","authors":"Kazunori Honda, Yusuke Kajimoto, Shiro Suzuki, Masahiko Mori, Kohshiro Nakao, Anri Azuma, Takashi Shibutani, Shoji Nagao, Takahiro Koyanagi, Izumi Kohara, Shuko Tamaki, Midori Yabuki, Lida Teng, Ataru Igarashi","doi":"10.1007/s10147-024-02668-z","DOIUrl":"https://doi.org/10.1007/s10147-024-02668-z","url":null,"abstract":"<p><strong>Background: </strong>Financial toxicity impacts the treatment choices, daily life, and health-related quality of life (HRQoL) of cancer patients. We investigated future variations in financial toxicity and HRQoL of patients with gynecologic cancer, evaluated using the COmprehensive Score for financial Toxicity (COST) questionnaire.</p><p><strong>Methods: </strong>This multicenter study enrolled patients with gynecologic cancer incurring co-payments for anti-cancer drug treatment for over 2 months. Questionnaires were administered at baseline and at the end of follow-up. Patients completed the COST, EORTC-QLQ-C30, EORTC-QLQ-OV28, EORTC-QLQ-CX24, EORTC-QLQ-EN24, and EQ-5D-5L. Paired t-tests were used to compare the initial and follow-up responses. Spearman's rank test was used to examine correlations between COST and HRQoL scores.</p><p><strong>Results: </strong>Ninety-one patients (ovarian, 40; cervical, 18; endometrial, 33) completed the questionnaires at baseline and follow-up. The mean COST score was not significantly different between baseline and end of follow-up (19.56 ± 6.63 and 19.97 ± 7.47, respectively; p = 0.439). Significant correlations were found between COST scores and emotional functioning (r = 0.251, p = 0.023), cognitive functioning (r = 0.254, p = 0.020), and financial difficulties (r = - 0.298, p = 0.006), attitude toward disease/treatment (r = 0.356, p = 0.033), poor body image (r = - 0.362, p = 0.042), back and pelvis pain (r = - 0.451, p = 0.010), and taste change (r = - 0.359, p = 0.040).</p><p><strong>Conclusions: </strong>During anticancer drug therapy for gynecologic cancer, the COST score remained stable and did not correlate with overall HRQoL, although higher scores were associated with worse HRQoL for specific functions and symptoms.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of aging on complications following robot-assisted radical prostatectomy.
IF 2.4 3区 医学
International Journal of Clinical Oncology Pub Date : 2024-12-02 DOI: 10.1007/s10147-024-02660-7
Shigeki Koterazawa, Masashi Kubota, Takayuki Sumiyoshi, Ryoichi Saito, Naoto Takaoka, Yuto Hattori, Yosuke Shimizu, Toru Kanno, Takeshi Soda, Yoshiyuki Okada, Kazunari Tsuchihashi, Yuya Sekine, Hiromitsu Negoro, Ryoma Kurahashi, Kimihiro Shimatani, Atsuro Sawada, Shusuke Akamatsu, Takayuki Goto, Takashi Kobayashi
{"title":"Effects of aging on complications following robot-assisted radical prostatectomy.","authors":"Shigeki Koterazawa, Masashi Kubota, Takayuki Sumiyoshi, Ryoichi Saito, Naoto Takaoka, Yuto Hattori, Yosuke Shimizu, Toru Kanno, Takeshi Soda, Yoshiyuki Okada, Kazunari Tsuchihashi, Yuya Sekine, Hiromitsu Negoro, Ryoma Kurahashi, Kimihiro Shimatani, Atsuro Sawada, Shusuke Akamatsu, Takayuki Goto, Takashi Kobayashi","doi":"10.1007/s10147-024-02660-7","DOIUrl":"https://doi.org/10.1007/s10147-024-02660-7","url":null,"abstract":"<p><strong>Background: </strong>For prostate cancer (PCa) in the elderly, including patients ≥ 80 years, the safety of robot-assisted radical prostatectomy (RARP) is controversial. We aimed to evaluate the effect of aging on the postoperative complication rates after RARP.</p><p><strong>Methods: </strong>This cohort study used a database of patients who had undergone RARP at 25 different institutes. We divided the cohort into four age groups (< 70, 70-74, 75-79, and ≥ 80 years). The complication rates after RARP in the 70-74, 75-79, and ≥ 80 year group were compared using the < 70 year group serving as the control group by applying the inverse probability of treatment weighting (IPTW)-adjusted regression analysis.</p><p><strong>Results: </strong>A total of 8055 patients were evaluated. The postoperative complication rates were 8.8%, 9.7%, 9.6%, and 10.0% in the < 70, 71-74, 75-79, and ≥ 80 age groups, respectively. In IPTW-adjusted analyses, the risk of overall complications (< 70 vs. 70-74 year group: OR = 1.09 [95% CI 0.92-1.29]; < 70 vs. 75-79 year group: OR = 1.09 [95% CI 0.88-1.37], and < 70 vs. ≥ 80 year group: OR = 2.21 [95% CI 0.92-5.32]) did not change with increasing age. There was no significant increase in risk for any complication category, such as bowel dysfunction, symptomatic lymphocele, or bacterial infection, between the < 70 and ≥ 80 age groups.</p><p><strong>Conclusion: </strong>Our findings showed that, in appropriately selected patients, the risk of complications after RARP did not increase with age, even at 75 or 80 years.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Out-of-pocket fertility preservation expenses: data from a Japanese nationwide multicenter survey. 自付生育力保存费用:来自日本全国多中心调查的数据。
IF 2.4 3区 医学
International Journal of Clinical Oncology Pub Date : 2024-12-01 Epub Date: 2024-09-04 DOI: 10.1007/s10147-024-02614-z
Masanori Ono, Yasushi Takai, Miyuki Harada, Akihito Horie, Yidan Dai, Eiji Kikuchi, Mitsuru Miyachi, Tetsuya Yamamoto, Nobuharu Fujii, Hiroaki Kajiyama, Atsushi Manabe, Toshiaki Yasuoka, Shinji Katsuragi, Keiko Mekaru, Tadashi Maezawa, Yuki Horage, Shinsuke Kataoka, Robert Nakayama, Takako Eguchi Nakajima, Fuminori Kimura, Chikako Shimizu, Kohei Sugimoto, Seido Takae, Yasushi Yumura, Hirotaka Nishi, Tatsuro Furui, Ken-Ichirou Morishige, Chie Watanabe, Yutaka Osuga, Nao Suzuki
{"title":"Out-of-pocket fertility preservation expenses: data from a Japanese nationwide multicenter survey.","authors":"Masanori Ono, Yasushi Takai, Miyuki Harada, Akihito Horie, Yidan Dai, Eiji Kikuchi, Mitsuru Miyachi, Tetsuya Yamamoto, Nobuharu Fujii, Hiroaki Kajiyama, Atsushi Manabe, Toshiaki Yasuoka, Shinji Katsuragi, Keiko Mekaru, Tadashi Maezawa, Yuki Horage, Shinsuke Kataoka, Robert Nakayama, Takako Eguchi Nakajima, Fuminori Kimura, Chikako Shimizu, Kohei Sugimoto, Seido Takae, Yasushi Yumura, Hirotaka Nishi, Tatsuro Furui, Ken-Ichirou Morishige, Chie Watanabe, Yutaka Osuga, Nao Suzuki","doi":"10.1007/s10147-024-02614-z","DOIUrl":"10.1007/s10147-024-02614-z","url":null,"abstract":"<p><strong>Background: </strong>The expenses related to fertility preservation or subsequent assisted reproductive treatments are significant for adolescents and young adult patients in Japan's current healthcare system. With fertility preservation becoming more widespread in developed countries, it is expected that these costs will be covered by insurance or subsidies. It is critical for patients, healthcare providers, and the government to know the costs that patients will be responsible for. In Japan, the costs of fertility preservation and subsequent assisted reproductive technology are not covered by insurance, but patients can apply for subsidies from the local and central governments if certain conditions are met. Presently, the above-mentioned costs, as well as the amount paid by the patient, vary by facility. Therefore, it is essential to ensure patients' continued access to necessary medical care despite the associated costs.</p><p><strong>Methods: </strong>In this study, questionnaires were mailed to 186 certified fertility preservation facilities in Japan to assess patients who had undergone fertility preservation or assisted reproduction. The questionnaires were sent between October 27, 2023 and March 31, 2024, with 140 of the 186 facilities responding (response rate: 75.3%).</p><p><strong>Results: </strong>Our findings show that approximately one-third of the costs was borne by the patients.</p><p><strong>Conclusion: </strong>Given these circumstances, sustainable pricing and insurance coverage are necessary for both patients and facilities.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1959-1966"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic landscape of cutaneous, acral, mucosal, and uveal melanoma in Japan: analysis of clinical comprehensive genomic profiling data. 日本皮肤、口腔、粘膜和葡萄膜黑色素瘤的基因组概况:临床综合基因组图谱数据分析。
IF 2.4 3区 医学
International Journal of Clinical Oncology Pub Date : 2024-12-01 Epub Date: 2024-09-09 DOI: 10.1007/s10147-024-02615-y
Tokimasa Hida, Junji Kato, Masashi Idogawa, Takashi Tokino, Hisashi Uhara
{"title":"Genomic landscape of cutaneous, acral, mucosal, and uveal melanoma in Japan: analysis of clinical comprehensive genomic profiling data.","authors":"Tokimasa Hida, Junji Kato, Masashi Idogawa, Takashi Tokino, Hisashi Uhara","doi":"10.1007/s10147-024-02615-y","DOIUrl":"10.1007/s10147-024-02615-y","url":null,"abstract":"<p><strong>Background: </strong>Cutaneous melanoma (CM) is the most common type in Caucasians, while acral melanoma (AM) and mucosal melanoma (MM), which are resistant to immunotherapies and BRAF/MEK-targeted therapies, are more common in East Asians. Genomic profiling is essential for treating melanomas, but such data are lacking in Japan.</p><p><strong>Methods: </strong>Comprehensive genomic profiling data compiled in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) were analyzed.</p><p><strong>Results: </strong>A total of 380 melanomas was analyzed, including 136 CM, 46 AM, 168 MM, and 30 uveal melanoma (UM). MM included conjunctival, sinonasal, oral, esophageal, anorectal, and vulvovaginal melanomas. No significant difference in the median tumor mutational burden (TMB) of CM (3.39 mutations/megabase), AM (2.76), and MM (3.78) was the key finding. Microsatellite instability-high status was found in one case. BRAF V600E/K was found in only 45 patients (12%). Key driver mutations in CM were BRAF (38%), NRAS (21%), NF1 (8%), and KIT (10%), with frequent copy number alterations (CNAs) of CDKN2A, CDKN2B, and MYC. AM was characterized by altered KIT (30%), NRAS (26%), and NF1 (11%) and CDKN2A, CDKN2B, CDK4, MDM2, and CCND1 CNAs. MM was characterized by altered NRAS (24%), KIT (21%), and NF1 (17%) and MYC, KIT, and CDKN2A CNAs, with differences based on anatomical locations. UM bore GNAQ or GNA11 driver mutations (87%) and frequent mutations in SF3B1 or BAP1.</p><p><strong>Conclusion: </strong>The distinct genomic profiling in Japanese patients, including lower TMB, compared to Caucasians, is associated with poorer treatment outcomes. This result underscores the need for more effective therapeutic agents.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1984-1998"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信